%20(2).png){kind=logo}
Senators are pushing to regulate or limit direct-to-consumer pharmaceutical advertising, raising concerns in the industry that such actions could threaten its $2 billion R&D investment model.
President Donald Trump signed on May 12 an executive order, the Most-Favored-Nation (MFN) prescription drug pricing policy, aimed to cut some U.S. medicine prices to match lower ones abroad.
The FDA's Elsa AI tool represents a pivotal step in integrating generative AI to streamline drug review processes and modernize regulatory practices.
The FDA's rollout of the AI tool "Elsa" was a predictable milestone in its broader, strategic shift toward generative AI-driven efficiencies in drug review processes, signaling the start of deeper transformative changes across regulatory operations.
The FDA's new generative AI tool, Elsa, is now accelerating clinical protocol reviews by summarizing data, identifying priorities, and streamlining workflows–marking a significant leap forward in regulatory review efficiency.
White Paper: Discover How Conversational AI Can Drive Engagement, Action, and Compliance for Your Brand
Havas today announced a strategic investment and partnership with Ostro, the trailblazing AI-powered engagement platform built for the life sciences industry
Join Ostro at Future Pharma in Boston this June to redefine AI-powered commercial strategies to improve the patient experience.
Ostro, the leading provider of AI-powered engagement solutions for life sciences, has filed a provisional U.S. patent application (US 19/036,907) titled "Machine Learning-Based Algorithms for Improved Generation of a Search Response."
.svg)